The interest by manufacturers to support users is very well appreciated. I think first of all an active exchange is beneficial in all cases. Generally, providing as much data as possible on the comparability of two instruments is very helpful. This would on the one hand be technical data (materials, such as capillary coatings or column materials, separation lengths, detector differences, ...) and on the other hand performance data (are readouts on both instruments comparable in complex products with complex sample preparations, how does the handling affect measurement variances etc.).

Join Dr. Anne Ries from Boehringer Ingelheim Pharma to explore Universal Study Design for Instrument Changes in Pharmaceutical Release Analytics.

Watch the On-Demand presentation now: https://bio-qc.com/best-practices-for-updating-analytical-procedures-in-drug-development-and-manufacturing/

Plus, don’t miss her expert insights during the panel discussion on Best Practices for Updating Analytical Procedures in Drug Development and Manufacturing.